Clinical trials
Refractory Large B-cell Lymphoma clinical trials
Below are recruiting refractory large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 226 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06743503RecruitingPhase 1
UB-VV400 with rapamycin for relapsed or refractory B-cell cancers
This trial tests a new combination therapy (UB-VV400 plus rapamycin) for people with B-cell cancers that have come back or not responded to previous treatment. It aims to see if this approach is safe and effective.
NanjingAges 18 years+ - NCT06735664RecruitingPhase 1
Zanubrutinib and odronextamab for Richter's transformation
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06723457RecruitingPhase 2
Epcoritamab and lenalidomide for immunodeficiency-related lymphoma
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
Chicago, IllinoisAges 18 years+ - NCT06213636RecruitingPhase 1/Phase 2
New CAR T cells for resistant B-cell leukemia or lymphoma
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 2–90 - NCT06707259RecruitingPhase 1
Cord blood CAR NK cells for B-cell lymphoma
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT06703892RecruitingPhase 1
CAR T-cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
TaipeiAges 18–70 - NCT06687772RecruitingPhase 2
Preventing brain relapse in high-risk lymphoma with stem cell transplant
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
St Louis, MissouriAges 18–75 - NCT06375733RecruitingPhase 1/Phase 2
GFH009 plus zanubrutinib for relapsed large B-cell lymphoma
This trial tests a new targeted drug (GFH009) combined with another targeted drug (zanubrutinib) for people with diffuse large B-cell lymphoma that has returned or not improved after at least two prior treatments. It aims to see if this combination can shrink tumors and improve outcomes.
NanningAges 18 years+ - NCT06672705RecruitingPhase 1
Epcoritamab for lymphoma that returns after an organ transplant
This study tests a drug called epcoritamab for people who have a type of lymphoma that developed after an organ transplant and has not responded to standard treatment. The drug aims to help your immune system fight the cancer cells.
St Louis, MissouriAges 18 years+ - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Tucson, ArizonaAges 18 years+ - NCT06446128RecruitingEarly Phase 1
CAR-T cell therapy for B-cell lymphoma that returned or didn't respond
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05607420RecruitingPhase 1/Phase 2
Testing a new cell therapy for relapsed lymphoma with CD20/CD22
This Phase 1/2 trial studies UCART20x22, a lab-made cell therapy, for people with certain types of relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (NHL). It may help by targeting lymphoma cells that carry CD20 and/or CD22 markers and then testing safety and early effectiveness.
Chicago, IllinoisAges 18–80 - NCT06570447RecruitingPhase 2
Glofitamab and chidamide for relapsed or refractory DLBCL
This trial tests a combination of two drugs, glofitamab and chidamide, for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The goal is to see if this combination can help when other options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06565689RecruitingPhase 1
YK012 for B-cell non-Hodgkin lymphoma after prior treatments
This study tests a new daily pill called YK012 for people with certain types of B-cell non-Hodgkin lymphoma that have not responded to at least two prior treatments. The goal is to see if it is safe and if it can shrink tumors.
Beijing, Beijing MunicipalityAges 18–65 - NCT06550141RecruitingPhase 2
Preventing side effects of CAR-T therapy for large B-cell lymphoma
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
Boston, MassachusettsAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT06542250RecruitingPhase 1/Phase 2
Study of a new immune therapy for relapsed B-cell cancers
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
La Jolla, CaliforniaAges 18 years+ - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Denver, ColoradoAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT06528301RecruitingPhase 1
Trial of UB-VV111 with or without rapamycin for B-cell cancers
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06526793RecruitingPhase 2
Surovatamig for relapsed or refractory B-cell lymphoma
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
Phoenix, ArizonaAges 18 years+ - NCT06508931RecruitingPhase 2
Zamtocabtagene autoleucel for children with B-cell lymphoma or leukemia
This trial tests a new CAR T-cell therapy (zamtocabtagene autoleucel) for children and teens whose B-cell lymphoma or leukemia has come back or hasn't responded to other treatments. The goal is to see if this one-time infusion can help their immune system fight the cancer.
Paris, Boulevard Sérurier 48Ages 6 months–17 years - NCT06484920RecruitingPhase 2
Pembrolizumab and ATRA for relapsed lymphoma
This trial tests a new combination of two medicines, pembrolizumab and ATRA (a form of vitamin A), for people with certain lymphomas that have come back or stopped responding to earlier treatments. The goal is to see if the combination can help the immune system fight the cancer more effectively.
Indianapolis, IndianaAges 18 years+ - NCT06486051RecruitingPhase 2
CAR T-cell therapy for adults with relapsed large B-cell lymphoma
This trial tests a new treatment called atlacabtagene autoleucel, which uses your own immune cells to fight the lymphoma. It's designed for people whose lymphoma has come back or not responded to initial treatments.
Auckland, AucklandAges 18–75
Hear when a new Refractory Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory large b-cell lymphoma?
- Yes. Clin2 currently lists 226 recruiting refractory large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Large B-cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.